<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000392</url>
  </required_header>
  <id_info>
    <org_study_id>N01 MH00013</org_study_id>
    <nct_id>NCT00000392</nct_id>
  </id_info>
  <brief_title>Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.</brief_title>
  <official_title>Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Mental Health (NIMH)</source>
  <brief_summary>
    <textblock>
      To evaluate the chemical efficacy and safety of intranasally administered peptide T on
      neurocognitive function in HIV seropositive individuals.

      Previous studies have shown that treatment with peptide T can result in cognitive improvement
      in HIV-infected patients.

      Patients are randomized to receive either peptide T or placebo for the first 6 months. All
      patients then receive open-label peptide T for approximately 6 additional months.
      Neuropsychologic tests are used to determine drug effects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 1990</start_date>
  <completion_date type="Actual">August 1996</completion_date>
  <primary_completion_date type="Actual">August 1996</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Global Neurocognitive Performance z Score From Baseline</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Higher values for change in z-score represent an improvement in Neurocognitive Performance (NP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Neurocognitive Performance Domain z Scores From Baseline</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Higher values for change in z-score represent an improvement in Neurocognitive Performance (NP)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>HIV Infections</condition>
  <condition>Cognition Disorders</condition>
  <arm_group>
    <arm_group_label>Peptide T</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peptide T</intervention_name>
    <arm_group_label>Peptide T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have:

               1. Cognitive dysfunction on neuropsychological testing.

               2. HIV antibody positivity.

               3. Expected survival of 6 months.

               4. EITHER no use of an antiretroviral within the past 4 weeks OR use of approved
                  regimens of AZT, ddI, or ddC.

               5. Medically stable EKG and urinalysis.

               6. Given informed, written consent to participate.

          -  Allowed:

               1. Inhaled aerosolized pentamidine for Pneumocystis carinii pneumonia prophylaxis,
                  dapsone, cotrimoxazole, topical antifungal agents, nystatin or ketoconazole,
                  acyclovir.

               2. Amitriptyline (up to 50 mg/day) or an equivalent dose of another antidepressant
                  for relief of peripheral neuropathy that is expected to remain unchanged
                  throughout the first 6 months of the study.

          -  Abstinence or agree to use barrier methods of birth control / contraception during the
             study

          -  Negative pregnancy test within 30 days of study entry

          -  Bilirubin &lt;= 3

          -  CD4 (Must be &lt;= 500 cells/mm3 if patient is without non-cognitive HIV-related
             symptoms. CD4 count &gt; 500 cells/mm3 allowed if patient has other (non-cognitive)
             HIV-related symptoms. ( 0 - 100 - 200 - 300 - 400 - 500 - 600 - 700 - 800 plus.)

          -  Creatinine &lt;= 1.5 mg/dl

          -  Granulocytes &gt;= 750

          -  Hemoglobin &gt; 8 g/dl (No more than two transfusions per month permitted.)

          -  Other Lab Values Prothrombin time &gt; 70 percent of control.

          -  Platelet Count &gt;= 75000 /mm3

          -  SGOT(AST) &lt; 5 x ULN (ULN = upper limit of normal).

        Exclusion Criteria:

          -  Patients with the following are excluded:

               1. History of mental retardation or learning disability.

               2. Evidence of current DSM-III-R Axis I disorder within 3 months prior to study
                  entry or past history of psychotic disorder or bipolar mania.

               3. History of neurologic disorder not secondary to HIV infection (e.g., head trauma
                  requiring medical observation or hospitalization, seizure disorder).

          -  Patients with the following symptoms or conditions are excluded:

               1. Kaposi's sarcoma or other malignancy likely to require chemotherapy during the
                  first 6 months of the study.

               2. Serious underlying medical problems that may complicate interpretation of the
                  treatment results, including unstable diabetes mellitus, severe arteriosclerotic
                  heart disease, uncontrolled hypertension, or hepatic or renal failure.

               3. Non-HIV related condition that is likely to interfere with interpretation of
                  neuropsychologic test results.

               4. Inability to participate in neuropsychologic testing or unable to comply with
                  intranasal study medication administration.

          -  Excluded within 4 weeks prior to study entry:

               1. Antiretrovirals except as allowed in the Patient Inclusion Criteria.

               2. Psychoactive agents (e.g., benzodiazepines, antidepressants, antipsychotics,
                  amphetamines)

        Excluded within 8 weeks prior to study entry:

        Long-acting psychoactive agents (e.g., Prozac).

          -  Active alcohol abuse in the past 3 months, or abuse judged by the investigators as
             likely to interfere with the analyses of neuropsychologic function. Abuse of cocaine,
             marijuana, heroin or other opiates (including methadone), barbiturates, amphetamines
             or other substances within the past 3 months, judged by the investigators as likely to
             interfere with the analyses of neuropsychologic tests.

          -  Positive pregnancy test within 30 days of study entry

          -  No abstinence or no agreement to use barrier methods of birth control / contraception
             during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Heseltine PN, Goodkin K, Atkinson JH, Vitiello B, Rochon J, Heaton RK, Eaton EM, Wilkie FL, Sobel E, Brown SJ, Feaster D, Schneider L, Goldschmidts WL, Stover ES. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol. 1998 Jan;55(1):41-51.</citation>
    <PMID>9443710</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2000</study_first_submitted>
  <study_first_submitted_qc>January 17, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2000</study_first_posted>
  <results_first_submitted>July 17, 2015</results_first_submitted>
  <results_first_submitted_qc>July 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 4, 2015</results_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Of 457 persons screened for cognitive impairment, 205 men and 10 women were randomized (106 to peptide T and 109 to placebo).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Peptide T</title>
          <description>Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months
Peptide T</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66">provided complete NP outcome data constituted the sample for the primary efficacy analyses</participants>
                <participants group_id="P2" count="77">provided complete NP outcome data constituted the sample for the primary efficacy analyses</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Peptide T</title>
          <description>Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months
Peptide T</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months
Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="109"/>
            <count group_id="B3" value="215"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Information is not available for all participants.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-39 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Information is not available for all participants.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Global Neurocognitive Performance z Score From Baseline</title>
        <description>Higher values for change in z-score represent an improvement in Neurocognitive Performance (NP)</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peptide T</title>
            <description>Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months
Peptide T</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Global Neurocognitive Performance z Score From Baseline</title>
          <description>Higher values for change in z-score represent an improvement in Neurocognitive Performance (NP)</description>
          <units>z score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.05"/>
                    <measurement group_id="O2" value="0.16" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Neurocognitive Performance Domain z Scores From Baseline</title>
        <description>Higher values for change in z-score represent an improvement in Neurocognitive Performance (NP)</description>
        <time_frame>Baseline and 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Peptide T</title>
            <description>Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months
Peptide T</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Neurocognitive Performance Domain z Scores From Baseline</title>
          <description>Higher values for change in z-score represent an improvement in Neurocognitive Performance (NP)</description>
          <units>z score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Verbal fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.09"/>
                    <measurement group_id="O2" value="0.15" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visuospatial ability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.06"/>
                    <measurement group_id="O2" value="0.25" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abstract thinking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.07"/>
                    <measurement group_id="O2" value="0.23" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Speed of information processing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.07"/>
                    <measurement group_id="O2" value="0.14" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Working memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" spread="0.09"/>
                    <measurement group_id="O2" value="0.08" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Learning and retention</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.07"/>
                    <measurement group_id="O2" value="0.11" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Motor performance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.06"/>
                    <measurement group_id="O2" value="0.18" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only data for the events that were statistically significant between the two treatment groups could be retrieved because adverse event data are lost.</desc>
      <group_list>
        <group group_id="E1">
          <title>Peptide T</title>
          <description>Peptide T given intranasally at a dosage of 2mg 3 times a day for 6 months
Peptide T</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo given intranasally at a dosage of 2mg 3 times a day for 6 months
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression or Irritability</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benedetto Vitiello, MD - Supervisory Medical Officer</name_or_title>
      <organization>NIMH</organization>
      <phone>301-443-3357</phone>
      <email>bvitiell@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

